AARD Stock: Aardvark Therapeutics, Inc. Common Stock Stock Price, Analysis & Insights
Get live aard stock price $11.51, comprehensive Aardvark Therapeutics, Inc. Common Stock stock analysis, charts, news, and expert forecast. Real-time aard stock data and investment insights.
Loading chart...
Company Overview
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Company Information
- CEO
- Tien-Li Lee
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
Contact Information
- Address
- 4370 La Jolla Village Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 3.62)
Business Model & Strategy
Aardvark Therapeutics, Inc. Common Stock operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Tien-Li Lee, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Aardvark Therapeutics, Inc. Common Stock competes in the Biotechnology within the broader Healthcare. With 250.6 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Aardvark Therapeutics, Inc. Common Stock provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Aardvark Therapeutics, Inc. Common Stock should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Aardvark Therapeutics, Inc. Common Stock shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Aardvark Therapeutics, Inc. Common Stock
- ⚠Investors should consider how Aardvark Therapeutics, Inc. Common Stock fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
250.61M
P/E Ratio
-4.68
Beta
3.62
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 250.61M market capitalization
- Trading Volume: 370.38K shares traded today
- Price Range: 52-week range of $4.88 - $19.58
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc. Common Stock (AARD) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 250.61M, the company represents a significant player in its market. The stock is currently trading at $11.51 with a positivedaily change of 24.30%.
The company's 22 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -4.68, beta of 3.62, and 52-week price range from $4.88 to $19.58when evaluating investment opportunities.
Why Invest in Aardvark Therapeutics, Inc. Common Stock?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Tien-Li Lee
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.